SYS-CON MEDIA Authors: Yeshim Deniz, Michael Bushong, Eric Brown, Gilad Parann-Nissany, Kevin Benedict

News Feed Item

Implant Sciences Hires New Director of Sales for Russia

Russia Projected to Spend $1.6 Billion on Transportation Security

WILMINGTON, MA -- (Marketwire) -- 01/24/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has retained Natalya Hall for the newly created position of Director of Sales for Russia and the Commonwealth of Independent States (CIS). In addition to Russia, Ms. Hall's region will include Belarus, Armenia, Azerbaijan, Estonia, Kazakhstan, Kyrgyzstan, Georgia, Latvia, Lithuania, Moldova, Turkmenistan, Tajikistan, Ukraine, and Uzbekistan. Ms. Hall will report directly to Joe Laskey, Area Vice President and General Manager of Asian Sales and Business Development. The Russian government announced in February of 2011 that it plans to spend $1.6 billion on transportation security for the three year period following the announcement.

With the addition of Ms. Hall, Implant Sciences continues to attract top industry talent to the Company. Ms. Hall was previously Regional Sales Manager for the Southeast United States at Bruker Corporation, a global provider of analytical instruments. Prior, she was Lead Analytical Chemist at Morpho Detection, a subsidiary of Safran, formerly GE Homeland Protection, where she led the development and release of two products, one of which was the worlds' first 2-in-1 chemical and biological agent identification instrument.

Furthermore, Ms. Hall was a part of the development of a government-sponsored explosives trace detection product, for which she received "Homeland Hero in Innovation" award from GE Homeland Protection. Ms. Hall also contributed to the development of the world's first simultaneous explosives and narcotics trace detector. She is the inventor of a particulate sampling technology that is patented in the U.S. and Europe. Ms. Hall received a B.S. Chemistry from the University of South Carolina.

"Natalya brings to us a very valuable and rare combination of both sales and technical expertise in trace detection along with her language and cultural skills for Russia and the CIS. We believe this large and growing market holds a great deal of potential for Implant Sciences, and with Natalya on board, we believe we will more effectively address region," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technological change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:

Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor Contact:
Laurel Moody
646-810-0608
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.